STOCK TITAN

[144] Beam Therapeutics Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144

Beam Therapeutics (BEAM) filed a Rule 144 notice disclosing a proposed sale of 25,000 common shares through Morgan Stanley Smith Barney LLC on the NASDAQ with an aggregate market value of $612,655.00. The filing reports 101,162,026 shares outstanding for the issuer.

The securities were acquired and paid for on 10/01/2025 by a stock option exercise from the issuer, with payment in cash. The filer reports no securities sold in the past three months and includes the standard representation that the seller is not aware of undisclosed material adverse information.

Beam Therapeutics (BEAM) ha presentato un avviso ai sensi della Regola 144 divulgando una vendita proposta di 25.000 azioni ordinarie tramite Morgan Stanley Smith Barney LLC sul NASAQ, con un valore di mercato aggregato di 612.655,00 USD. La documentazione riporta 101.162.026 azioni ordinarie in circolazione per l’emittente.

I titoli sono stati acquisiti e pagati il 01/10/2025 tramite un esercizio di opzioni su azioni dell’emittente, con pagamento in contanti. Il dichiarante segnala di non aver venduto titoli nei ultimi tre mesi e include la dichiarazione standard secondo cui il venditore non è a conoscenza di informazioni sostanzialmente avverse non disclosure.

Beam Therapeutics (BEAM) presentó un aviso conforme a la Regla 144 divulgando una venta propuesta de 25,000 acciones ordinarias a través de Morgan Stanley Smith Barney LLC en el NASDAQ con un valor de mercado agregado de $612,655.00. El archivo reporta 101,162,026 acciones en circulación para el emisor.

Los valores fueron adquiridos y pagados el 01/10/2025 mediante un ejercicio de opción sobre acciones por parte del emisor, con pago en efectivo. El presentante reporta que no ha vendido valores en los últimos tres meses e incluye la declaración estándar de que el vendedor no tiene conocimiento de información sustancial adversa no divulgada.

Beam Therapeutics (BEAM)Rule 144에 따라 Morgan Stanley Smith Barney LLC를 통해 NASDAQ에서 25,000 일반주의 제안된 매각을 공개하는 공시를 제출했고, 총 시장가치는 612,655.00 USD입니다. 공시는 발행사의 상장주식 수 101,162,026주를 보고합니다.

해당 증권은 발행사의 주식 매수선택권 행사2025-10-01에 취득되어 현금으로 지급되었습니다. 제출자는 지난 3개월 동안 증권을 매도한 적이 없다고 보고하며, 매도인이 공표되지 않은 중대한 불리한 정보를 모르는 표준 진술을 포함합니다.

Beam Therapeutics (BEAM) a déposé un avis selon la règle 144 divulguant une vente proposée de 25 000 actions ordinaires par l’intermédiaire de Morgan Stanley Smith Barney LLC sur le NASDAQ, d’une valeur marchande globale de 612 655,00 USD. Le dossier indique 101 162 026 actions en circulation pour l’émetteur.

Les titres ont été acquis et payés le 01/10/2025 par un exercice d’options sur actions de l’émetteur, avec paiement en espèces. Le déclarant indique ne pas avoir vendu de titres au cours des trois derniers mois et inclut la déclaration standard selon laquelle le vendeur n’est pas au courant d’informations défavorables importantes non divulguées.

Beam Therapeutics (BEAM) hat gemäß der Rule 144 eine Mitteilung eingereicht, die einen vorgeschlagenen Verkauf von 25.000 Stammaktien über Morgan Stanley Smith Barney LLC an der NASDAQ mit einem Gesamtmarktwert von 612.655,00 USD offenlegt. Die Einreichung meldet 101.162.026 ausstehende Aktien des Emittenten.

Die Wertpapiere wurden am 01.10.2025 durch ein Ausüben von Aktienoptionen des Emittenten erworben und bar bezahlt. Der Einreicher gibt an, in den letzten drei Monaten keine Wertpapiere verkauft zu haben, und enthält die Standarderklärung, dass dem Verkäufer keine nicht offengelegten wesentlichen nachteiligen Informationen bekannt sind.

Beam Therapeutics (BEAM) قدمت إشعاراً بموجب القاعدة 144 يكشف عن بيع مقترح لـ 25,000 سهم عادي من خلال Morgan Stanley Smith Barney LLC في ناسداك بقيمة سوقية إجمالية قدرها $612,655.00. وتذكر الوثيقة وجود 101,162,026 سهمًا قائماً للمصدر.

تم شراء الأوراق المالية ودفع ثمنها في 01/10/2025 من خلال ممارسة خيار أسهم من المُصدر، مع الدفع نقداً. يذكر المُبلغ أن لا توجد مبيعات لأي أوراق مالية خلال الأشهر الثلاثة الأخيرة ويتضمن البيان القياسي بأن البائع ليس على علم بمعلومات جوهرية سلبية غير معلنة.

Beam Therapeutics (BEAM) 已提交一份Rule 144通知,披露拟通过 Morgan Stanley Smith Barney LLC 在 NASDAQ 出售 25,000 股普通股,总市值为 612,655.00 美元。该发行人的在外流通股数为 101,162,026 股

证券于 2025-10-01 通过发行人发起的股票期权行使获得并以现金支付。申报人表示在过去三个月内未出售任何证券,并包含卖方不知道未披露的重大不利信息的标准声明。

Positive
  • Rule 144 disclosure provided, documenting the proposed sale and acquisition method
  • Transaction routed through a major broker (Morgan Stanley Smith Barney LLC), indicating standard execution channels
Negative
  • None.

Insights

TL;DR: Rule 144 notice discloses a single 25,000-share sale acquired by option exercise and routed through a major broker.

The filing is a routine insider liquidity disclosure under Rule 144. It specifies the number of shares, aggregate market value, acquisition method (stock option exercise), payment method (cash), and the broker handling the sale. The reported outstanding share count (101,162,026) provides context on scale. No recent sales in the prior three months are reported. The submission contains the standard attestation regarding material nonpublic information. This notice is procedural and informational rather than a corporate operational disclosure.

TL;DR: Disclosure aligns with Rule 144 requirements; the filing documents insider sale mechanics but contains no governance events.

The document fulfills required insider reporting by identifying the sale mechanics and broker. It records acquisition via an issuer stock option exercise and immediate proposed sale, which is common in equity compensation cases. The filing does not name the selling person in the visible content, nor does it present any leadership changes, related-party transactions, or governance actions. As presented, the filing raises no governance flags and appears compliant with disclosure norms.

Beam Therapeutics (BEAM) ha presentato un avviso ai sensi della Regola 144 divulgando una vendita proposta di 25.000 azioni ordinarie tramite Morgan Stanley Smith Barney LLC sul NASAQ, con un valore di mercato aggregato di 612.655,00 USD. La documentazione riporta 101.162.026 azioni ordinarie in circolazione per l’emittente.

I titoli sono stati acquisiti e pagati il 01/10/2025 tramite un esercizio di opzioni su azioni dell’emittente, con pagamento in contanti. Il dichiarante segnala di non aver venduto titoli nei ultimi tre mesi e include la dichiarazione standard secondo cui il venditore non è a conoscenza di informazioni sostanzialmente avverse non disclosure.

Beam Therapeutics (BEAM) presentó un aviso conforme a la Regla 144 divulgando una venta propuesta de 25,000 acciones ordinarias a través de Morgan Stanley Smith Barney LLC en el NASDAQ con un valor de mercado agregado de $612,655.00. El archivo reporta 101,162,026 acciones en circulación para el emisor.

Los valores fueron adquiridos y pagados el 01/10/2025 mediante un ejercicio de opción sobre acciones por parte del emisor, con pago en efectivo. El presentante reporta que no ha vendido valores en los últimos tres meses e incluye la declaración estándar de que el vendedor no tiene conocimiento de información sustancial adversa no divulgada.

Beam Therapeutics (BEAM)Rule 144에 따라 Morgan Stanley Smith Barney LLC를 통해 NASDAQ에서 25,000 일반주의 제안된 매각을 공개하는 공시를 제출했고, 총 시장가치는 612,655.00 USD입니다. 공시는 발행사의 상장주식 수 101,162,026주를 보고합니다.

해당 증권은 발행사의 주식 매수선택권 행사2025-10-01에 취득되어 현금으로 지급되었습니다. 제출자는 지난 3개월 동안 증권을 매도한 적이 없다고 보고하며, 매도인이 공표되지 않은 중대한 불리한 정보를 모르는 표준 진술을 포함합니다.

Beam Therapeutics (BEAM) a déposé un avis selon la règle 144 divulguant une vente proposée de 25 000 actions ordinaires par l’intermédiaire de Morgan Stanley Smith Barney LLC sur le NASDAQ, d’une valeur marchande globale de 612 655,00 USD. Le dossier indique 101 162 026 actions en circulation pour l’émetteur.

Les titres ont été acquis et payés le 01/10/2025 par un exercice d’options sur actions de l’émetteur, avec paiement en espèces. Le déclarant indique ne pas avoir vendu de titres au cours des trois derniers mois et inclut la déclaration standard selon laquelle le vendeur n’est pas au courant d’informations défavorables importantes non divulguées.

Beam Therapeutics (BEAM) hat gemäß der Rule 144 eine Mitteilung eingereicht, die einen vorgeschlagenen Verkauf von 25.000 Stammaktien über Morgan Stanley Smith Barney LLC an der NASDAQ mit einem Gesamtmarktwert von 612.655,00 USD offenlegt. Die Einreichung meldet 101.162.026 ausstehende Aktien des Emittenten.

Die Wertpapiere wurden am 01.10.2025 durch ein Ausüben von Aktienoptionen des Emittenten erworben und bar bezahlt. Der Einreicher gibt an, in den letzten drei Monaten keine Wertpapiere verkauft zu haben, und enthält die Standarderklärung, dass dem Verkäufer keine nicht offengelegten wesentlichen nachteiligen Informationen bekannt sind.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What did the BEAM Form 144 disclose about the proposed sale?

The filing disclosed a proposed sale of 25,000 common shares with an aggregate market value of $612,655.00 on the NASDAQ.

How were the shares acquired that are being sold under the BEAM Form 144?

The shares were acquired on 10/01/2025 by stock option exercise from the issuer and paid for in cash.

Which broker is handling the proposed BEAM share sale?

Morgan Stanley Smith Barney LLC is named as the broker in the filing.

How many shares outstanding does the filing report for BEAM?

The filing reports 101,162,026 shares outstanding for the issuer.

Did the filer report any securities sold in the past three months?

No; the filing states "Nothing to Report" for securities sold during the past three months.
Beam Therapeutics Inc.

NASDAQ:BEAM

BEAM Rankings

BEAM Latest News

BEAM Latest SEC Filings

BEAM Stock Data

2.59B
99.87M
1.19%
105.17%
25.19%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
CAMBRIDGE